Factors predictive of the response to interferon in patients with chronic hepatitis C

Journal of Hepatology

Volumn 21, Issue 1, 1994, Pages 12-17

  Serfaty, Lawrence ^a   Giral, Philippe ^a   Loria, Alain ^a   Andréani, Tony ^a   Legendre, Claire ^a   Poupon, Raoul ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Bile acids; Cholestasis; Chronic hepatitis C; Interferon; Viral hepatitis treatment

Indexed keywords

BILE ACID; RECOMBINANT ALPHA2 INTERFERON;

ADULT; ARTICLE; CHOLESTASIS; CHRONIC HEPATITIS; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEPATITIS C; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL;

ADULT; ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; BLOOD CHEMICAL ANALYSIS; BLOOD PROTEINS; FEMALE; HEPATITIS C; HUMAN; INTERFERON TYPE I, RECOMBINANT; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 0027934395     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(94)80130-4     Document Type: Article

References (33)

1. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
2. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial
3. Recombinant human alfa interferon in patients with chronic non-A, non-B hepatitis a multicenter randomized controlled trial from France
4. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis
5. Interferon for non-A non-B hepatitis A meta-analysis of randomised clinical trials
6. Absence of efficacy of an increasing dosage schedule on the response rate during and after recombinant alfa interferon therapy in chronic hepatitis C (Abstract)
7. High doses of recombinant alfa interferon or gamma interferon for chronic hepatitis C: a randomized, controlled trial
8. Twelve-month treatment, compared to 6-month treatment, does not improve the efficacy of alfa-interferon in NANB chronic active hepatitis (Abstract)
9. Treatment of chronic hepatitis C with different regimens of interferon alpha-2a (IFN-2a) (Abstract)
10. Which patients with chronic hepatitis B virus infection will respond to alfa-interferon therapy ? A statistical analysis of predictive factors
11. Therapy of chronic hepatitis C with alfa interferon: the answer? Or more questions?
12. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
13. Alpha-interferon 2b (IFN) in the treatment of chronic active hepatitis C: interim report of the first multicentre Australian trial (Abstract)
14. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness of interferon therapy in viremic patients
15. Factors predictive of a response to interferon therapy in NANB chronic active hepatitis (Abstract)
16. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alfa therapy: relationship to genotypes of hepatitis C virus
17. Traitement par l'interferon alpha-2a de 26 cas d'hépatites chroniques non-A non-B
18. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis
19. Biochemical markers of hepatic fibrosis
20. Measurements of iron status in patients with chronic hepatitis
21. Responses to alfa interferon (IFN) therapy are influenced by the iron content of liver (Abstract)
22. Factors predicting early response to treatment with recombinant interferon alpha-2a in chronic non-A, non-B hepatitis. Preliminary report of a long-term trial
23. Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse
24. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alfa production by monocytes
25. Mechanisms of action of interferons
26. The interferons. Mechanisms of action and clinical applications
27. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C
28. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy
29. Three different patterns of hepatitis C virus infection in chimpanzees
30. Letter to the Editor
31. Virological background factors affecting interferon therapy in chronic hepatitis C (abstract)
32. IFN alfa 2b therapy of viral hepatitis following liver transplantation (Abstract)